← All stocks

Cerenome, Inc.

PSTVPharmaceuticalsLatest filing used: 2026-11-13Filings on SEC EDGAR ↗

Fair value per share

No filings-based value

The filings alone are probably missing something here: the company's typical cash earnings in the filings are negative.

How we decide

Ten years of results

Revenue

$5M in FY2025, down 10% on the year before

FY2012: $9MFY2013: $7MFY2014: $5MFY2015: $5MFY2016: $5MFY2017: $3MFY2018: $4MFY2023: $5MFY2024: $6MFY2025: $5M$5M$10MFY12FY15FY18FY25$5.2M
Show as table
YearRevenue
FY2012$9M
FY2013$7M
FY2014$5M
FY2015$5M
FY2016$5M
FY2017$3M
FY2018$4M
FY2023$5M
FY2024$6M
FY2025$5M

Cash earnings as a share of sales

-313.2% of sales in FY2025

FY2023: -195.2%FY2024: -271.5%FY2025: -313.2%-313%-107%100%FY12FY15FY18FY25-313%
Show as table
YearCash earnings as a share of sales
FY2012–
FY2013–
FY2014–
FY2015–
FY2016–
FY2017–
FY2018–
FY2023-195.2%
FY2024-271.5%
FY2025-313.2%

Shares outstanding

Share count rose 2377% over 9 years

FY2023: 3MFY2024: 8MFY2025: 78M040M80MFY12FY15FY18FY2577.8M
Show as table
YearShares outstanding
FY2012–
FY2013–
FY2014–
FY2015–
FY2016–
FY2017–
FY2018–
FY20233M
FY20248M
FY202578M

No dividends paid in these years.

Delayed quote

Delayed price and chart from TradingView. This site does not receive or store these prices, and the fair value above does not use them. Showing the chart sends TradingView this page's address, the widget type, the ticker and your IP address, and TradingView may collect analytics; see Privacy.

Open on Yahoo Finance ↗

Sources. Company figures: SEC EDGAR (XBRL filings), latest filing used 2026-11-13. Interest rate: U.S. Treasury, 10-year par yield, 2026-11-13.